Tvardi Therapeutics, Inc. (TVRD) · Nov 19, 2026 · Other events
Pre-IND feedback — FDA supports the Phase 2 approach; IND submission planned for 2027, subject to funding
Tvardi Therapeutics’ FDA pre-IND feedback supports TTI-109’s Phase 2 path in IBD, but IND clearance and new funding remain key hurdles.
Tvardi is a cash-constrained clinical-stage biotech trying to move TTI-109 from a completed healthy-volunteer study into ulcerative-colitis development, while its separate TTI-101 liver-cancer program approaches a 2027 data readout. The company had $22.3 million of cash at September 30, 2026, and said its existing funds should support operations into the third quarter of 2027—but advancing TTI-109 still requires additional funding.
The FDA has removed a regulatory design obstacle, not the development obstacle. The agency agreed that the proposed nonclinical package was appropriate to support a Phase 2 trial and gave guidance on dosing, study design, and patient selection. 〔0〕 That is useful executional progress, but management explicitly said the feedback was “in line with our expectations,” so this is confirmation and added detail rather than a clear regulatory surprise.
The new biology strengthens the product concept, but remains unproven in patients. Tvardi’s analysis of healthy-volunteer exposure versus cell-culture thresholds supports sustained STAT3 inhibition with minimal predicted STAT1 and STAT5 inhibition. 〔1〕 That could support a differentiated safety argument versus broader JAK inhibition, but it is modeled from healthy-volunteer and in-vitro data; patient safety and clinical benefit remain unknown.
The financing caveat keeps this from being a clean step-change. Tvardi plans to submit the IND in 2027, but Phase 2 initiation remains contingent on both FDA clearance and additional capital. 〔2〕 The event advances the program on paper while leaving the company’s ability to fund the next clinical step unresolved.
Bottom line: This is modestly constructive because the FDA supports Tvardi’s Phase 2 plan and gives it a clearer route to an IND. It does not materially de-risk the program yet: funding, IND clearance, and patient data remain ahead of the company.
TTI-101 HCC topline data, early first quarter 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!